Estimates that it will have cash, cash equivalents and marketable securities of $30M-$35M as of June 30, 2025, which is expected to fund its current operations into the second half of 2026. “We recently presented preclinical proof-of-concept data for EO-1022, reaffirming its potential as a differentiated HER3 ADC, and supporting our goal of providing a safer and more effective option for patients with HER3-expressing solid tumors,” said CEO Joseph Ferra. “In parallel, we are engaged in efforts to explore a range of strategic alternatives, with the objective of identifying and capitalizing on the opportunity that is in the best interest of our shareholders. We look forward to providing an update at the appropriate time.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELEV:
- Elevation Oncology’s Chief Medical Officer Steps Down
- Boeing upgraded, Lockheed downgraded: Wall Street’s top analyst calls
- Elevation Oncology: Strategic Shift to EO-1022 Amidst EO-3021 Discontinuation Justifies Hold Rating
- Elevation Oncology downgraded to Equal Weight from Overweight at Stephens
- Elevation Oncology price target lowered to $1 from $6 at H.C. Wainwright